Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
- Conditions
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 204
- Registration Number
- NCT04952753
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸University of Michigan Medical, Ann Arbor, Michigan, United States
🇺🇸WA Uni School Of Med, Saint Louis, Missouri, United States
A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 94
- Registration Number
- NCT04948697
- Locations
- 🇨🇳
Chongqing University Three Gorges Hospital, Chongqing, Chongqing, China
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, Taiwan
The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)
- Conditions
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 68
- Registration Number
- NCT04948034
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Quanli Gao
- Target Recruit Count
- 9
- Registration Number
- NCT04924413
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT04921995
- Locations
- 🇨🇳
Eye and ENT Hospital of Fudan University, Shanghai, China
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 377
- Registration Number
- NCT04921358
- Locations
- 🇨🇳
Xinqiao Hospital Affiliated to the Army Medical University, Chongqing, Chongqing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇦🇺The Northern Hospital, Epping, Victoria, Australia
Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 265
- Registration Number
- NCT04913571
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Sichuan Provincial People's Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT04914390
- Locations
- 🇨🇳
Department of breast surgery, Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04909775
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Changhai Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT04902261
- Locations
- 🇨🇳
Changhai Hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.